MacroGenics, Inc.

MacroGenics, Inc. is a clinical-stage biopharmaceutical company that develops antibody-based therapeutics for cancer. The company's drug development pipeline requires extensive preclinical testing, which includes animal studies as a standard and mandatory component of regulatory compliance. Its public filings and clinical trial documentation explicitly reference the use of animal models in its research.

The company's development programs, such as those for its bispecific antibodies and antibody-drug conjugates, involve in vivo studies in animal models to assess efficacy and safety before advancing to human clinical trials. For instance, one of its investigational candidates, MGD014, was evaluated in "HIV-1-infected humanized mice" in preclinical studies. MacroGenics acknowledges in its regulatory submissions that it must comply with the Animal Welfare Act and other regulations governing animal research.

As a biotechnology firm whose core business is advancing novel drug candidates through the FDA approval process, MacroGenics' operations are fundamentally reliant on animal testing. There is no evidence the company has developed or committed to alternative testing methods that would replace animal use across its pipeline.